• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy Coronary Heart Disease
Conclusions Our analysis suggests that the CRUSADE score predicts major bleeding similarly to ACUITY and better than HAS BLED in an all-comer population with percutaneous coronary intervention and potentially identifies patients at higher risk of hemorrhagic complications when treated with a long-term dual antiplatelet therapy regimen. Clinical Trial Registration URL: http://clinicaltrials.gov. Unique identifier: NCT00611286.
Source: JAHA:Journal of the American Heart Association - December 7, 2015 Category: Cardiology Authors: Costa, F., Tijssen, J. G., Ariotti, S., Giatti, S., Moscarella, E., Guastaroba, P., De Palma, R., Ando, G., Oreto, G., Zijlstra, F., Valgimigli, M. Tags: Coronary Heart Disease Source Type: research

Predictors of Long-term Clinical Endpoints in Patients With Refractory Angina Coronary Heart Disease
Conclusions Clinically stable patients with RA who are medically managed have a modest mortality, but a high incidence of hospitalization and resource use over 3 years. These findings point to the need for novel therapies aimed at symptom mitigation in this population and their potential impact on health care utilization and costs.
Source: JAHA:Journal of the American Heart Association - January 30, 2015 Category: Cardiology Authors: Povsic, T. J., Broderick, S., Anstrom, K. J., Shaw, L. K., Ohman, E. M., Eisenstein, E. L., Smith, P. K., Alexander, J. H. Tags: Coronary Heart Disease Source Type: research

Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry Coronary Heart Disease
Conclusions With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.
Source: JAHA:Journal of the American Heart Association - April 14, 2014 Category: Cardiology Authors: Sherwood, M. W., Wiviott, S. D., Peng, S. A., Roe, M. T., DeLemos, J., Peterson, E. D., Wang, T. Y. Tags: Coronary Heart Disease Source Type: research